Menu
← Oncology Approval Tracker
FDA DECISION ·
Rezlidhia
olutasidenib · Rigel Pharmaceuticals
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with relapsed or refractory AML and a susceptible IDH1 mutation identified by an FDA-approved test.
LAMPGEN ANALYSIS
Why it matters
The action adds an IDH1-directed option for previously treated AML.
What research teams should watch
Confirm mutation testing and implement a plan to recognize and escalate differentiation syndrome.
PRIMARY RECORDS